Inhibitors of nek7 kinase
AssigneeHalia Therapeutics, Inc.
InventorsDavid James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard
Life of this patent
Estimating the term…
Abstract
Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein, A, X, Y, R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of the NLRP3 inflammasome are also provided.
Claims21
1-52. (canceled)
A compound having one of the following structures:
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or excipient and a compound having one of the following structures:
- or a pharmaceutically acceptable salt thereof.
A method of treating a NLRP3-mediated disorder, comprising administering a therapeutically effective amount of a compound having one of the following structures:
- or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the disorder is selected from type II diabetes, atherosclerosis, Alzheimer's disease, fatty liver, asthma, psoriasis, obesity, acute and chronic tissue damage caused by infection, gout, arthritis, macular degeneration, enteritis, hepatitis, peritonitis, silicosis, UV-induced skin sunburn, contact hypersensitivity, sepsis, cancer, neurodegenerative disease, multiple sclerosis, Muckle-Wells syndrome, and myelodysplastic syndrome (MDS).
Dependencies are inferred from the claim text.